Edwards Lifesciences Corporation Deferred Revenue
Edwards Lifesciences Corporation (EW) had Deferred Revenue of $5.30 million as of 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2018-04-27
- 2018-03-31: Deferred Revenue $5.30M.
- 2017-12-31: Deferred Revenue $4.20M.
| Period end | Deferred Revenue |
|---|---|
| 2018-03-31 | $5.30M 10-Q · filed 2018-04-27 |
| 2017-12-31 | $4.20M 10-Q · filed 2018-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |